LOVE and 8CB0 Related Headlines
Go Back- Cannara Announces Graduation to the Toronto Stock Exchange
- Cannara to Host Investor Webcast on February 19th, 2026
- Cannara Biotech raises C$6.3 million in private placement at premium
- Cannara Announces Strategic C$6.3 Million Non-Brokered Private Placement Priced at C$2.10 per Common Share
- Cannara Announces Conditional Approval to List on the Toronto Stock Exchange
- Cannara Reports Q1 Fiscal 2026 Results, Delivers New Record Financial Results, Extends Market Share Gains and Advances Disciplined Expansion Strategy
- Cannara Achieves OTCQX Qualification and Announces Release of Fiscal Q1 2026 Financial Results on January 26, 2026
- Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch
- Cannara Biotech Delivers Record Fiscal 2025 Revenue and Profitability, Achieves First Year of Positive Retained Earnings
- Cannara Biotech Inc. to Announce Fiscal Q4 2025 and Fiscal Year 2025 Financial Results on November 24, 2025 and Provides Board Update
- Cannara Announces DTC Eligibility to Facilitate U.S. Investor Access and Strengthens Balance Sheet through completion of Debt-to-Equity Conversion
- Cannara Announces Proposed Settlement of Convertible Debenture via Share Issuance
LOVE and 8CB0 Related Press Releases
Go Back- Cannara Announces Graduation to the Toronto Stock Exchange
- Cannara to Host Investor Webcast on February 19th, 2026
- Cannara Announces Strategic C$6.3 Million Non-Brokered Private Placement Priced at C$2.10 per Common Share
- Cannara Announces Conditional Approval to List on the Toronto Stock Exchange
- Cannara Reports Q1 Fiscal 2026 Results, Delivers New Record Financial Results, Extends Market Share Gains and Advances Disciplined Expansion Strategy
- Cannara Achieves OTCQX Qualification and Announces Release of Fiscal Q1 2026 Financial Results on January 26, 2026
- Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch
- Cannara Biotech Delivers Record Fiscal 2025 Revenue and Profitability, Achieves First Year of Positive Retained Earnings
- Cannara Biotech Inc. to Announce Fiscal Q4 2025 and Fiscal Year 2025 Financial Results on November 24, 2025 and Provides Board Update
- Cannara Announces DTC Eligibility to Facilitate U.S. Investor Access and Strengthens Balance Sheet through completion of Debt-to-Equity Conversion
- Cannara Announces Proposed Settlement of Convertible Debenture via Share Issuance
